HIV and opportunistic infections Flashcards

1
Q

who gets opportunistic infections

A
  • immunodeficient
  • chemo pts
  • chronic steroid use
  • elderly
  • transplant pts
  • generally associated with T cell immunosuppression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the common fungal opportunistic infections

A
  • cryptococcus
  • histoplasma
  • candida
  • pneumocystis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the common viral opportunistic infections

A
  • CMV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the common parasitic opportunistic infections

A
  • toxoplasma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

risk factors for fungal opportunistic infections

A
  • severity of T cell mediated immunity
  • recent or current use of antifungals
  • risk of exposure
  • neutropenia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how is cryptococcus transmitted

A
  • air droplets and bird droppings
  • spores inhaled -> lodged into lung alveoli -> dissemination -> infection
  • is a fungus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

clinical manifestations of cryptococcus

A
  • meningitis*
  • insidious onset
  • altered mental status* - usually irritable
  • papilledema*
  • malaise, fever
  • n/v
  • fullness in ears
  • CT will be normal
  • opening pressure during LP will be very high
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

diagnosis of cryptococcus

A
  • test for antigen in CSF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

treatment of cryptococcus

A
  • amphotericin B

- fluconazole*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how is histoplasmosis transmitted

A
  • inhalation
  • exposure to chicken coops
  • endemic to certain parts of US
  • is a fungus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

clinical manifestations of histoplasmosis

A
  • 1-3 mo after exposure
  • fever
  • weight loss*
  • dyspnea on exertion
  • skin ulcers*
  • hepatosplenomegaly
  • lymphadenopathy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

diagnosis of histoplasmosis

A
  • urine test

- h. capsulatium antigen sensitivity in urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

treatment of histoplasmosis

A
  • amphotericin b

- itraconazole*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the CD4 counts where candidiasis infections occur

A
  • < 300

- esophagitis may also occur when <100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is the most common cause of dysphagia and odynophagia in AIDS pts

A
  • candidiasis

- is a fungus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

treatment for candidiasis

A
  • fluconazole*

- avoid topical treatments d/t low cure rate and high relapse rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

diagnosis

A
  • gold standard= EGD endoscopy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

clinical manifestations of candidiasis

A
  • burning/ stabbing in mouth and/or throat
  • white markings with surrounding erythema
  • raised tissue
  • not uncommon to have candidiasis, herpes, and CMV co-infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

how is pneumocystis jirovecii transmitted

A
  • attach to alveolar epithelium -> inflammation, interstitial edema, diffuse alveolar damage
  • enviornmental exposure is main cause
  • fungus with tropism for lungs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

clinical presentation of pneumocystis jirovecii

A
  • gradual onset
  • fever
  • dry cough
  • dyspnea
  • average 1 month before medical consut
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

diagnosis of pneumocystis jirovecii

A
  • imaging- HRCT chest

- lab- BAL immunoflorescence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

treatment of pneumocystis jirovecii

A
  • bactrim
  • either IV or PO X 21 days
  • steroids
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

at what CD4 level does CMV infection occur?

A
  • <50
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

CMV clinical manifestations

A
  • mainly affects retina
  • no pain
  • floaters, blurred vision, decreased peripheral vision
  • light flashes
  • sudden vision loss
  • starts in 1 eye but usually involves both
  • blindness d/t retinal detachment
  • *** any acute vision loss, young, and immunosuppressed is CMV until proven otherwise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

diagnosis of CMV

A
  • perivascular fluffy yellow-white retinal infiltrate +/- hemorrhage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

treatment of CMV

A
  • IV ganciclovir
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

at what CD4 count does toxoplasmosis infection occur?

A
  • CD4 <100 has 30% risk without ppx

- CD4 < 50 has 75% annual risk without ppx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

what causes toxoplasmosis

A
  • t. gondii

- 30% of people in US are seropositive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

clinical manifestations of toxoplasmosis

A
  • HA
  • confusion
  • fever
  • lethargy
  • seizures
  • altered mental status
  • psychomotor retardation
  • may mimic lymphoma
30
Q

diagnosis of toxoplasmosis

A
  • IgG serology for t. gondii
  • order MRI
  • LP for malignant cells and EBV, order PCR for t. gondii
  • brain biopsy if no clinical or radiological improvement after 2 weeks tx
31
Q

treatment of toxoplasmosis

A
  • pyrimethamine + sulfadiazine + leucovorin
32
Q

how the HIV virus works

A

1. attaches to host cell via CD4 cells and coreceptors
2. fusion, RNA virus sends out genetic material
3
. reverse transcriptase makes RNA into DNA
4. DNA is integrated into host DNA via integrase
5. DNA -> RNA -> viral proteins
6
. new virus formed, protease assembles mature proteins
*= target of drug therapy

33
Q

stages of HIV infection

A
  • early infection
  • clinical latency
  • AIDS
34
Q

when do you diagnose someone with AIDS

A
  • CD4 <200

- dx with AIDS defining condition

35
Q

general course of infection in untreated pt

A
  • first few weeks VL is detectable (once it hits 50)
  • weeks 3-6 VL peaks then spontaneously drops
  • VERY contagious during peak
  • CD4 dips down during acute infections
  • over years CD4 drops and VL increases
  • 7-10 years in untreated pt until AIDS dx or death
36
Q

what labs do you order when HIV is suspected

A
  • VL
  • CD4 count
  • Hep B and C
  • Toxicology
  • STD tests
  • PPD
  • CMV
  • make sure vaccines are up to date
37
Q

what are the parameters for positive PPD test

A
  • health care worker- 10 mm
  • general population- 15 mm
  • HIV- 5 mm
38
Q

who is at the highest risk for HIV infection

A
  • MSM
  • heterosexual women
  • IVDU
  • minorities
  • ages 25-35 highest risk new dx
  • ages 35-44 second highest risk new dx
39
Q

what are HIV transmission risk factors

A
  • VL
  • lack of circumcision
  • sexual partners
  • sexual practice
  • STD- ulcers increase risk by 4X
  • genetics
40
Q

what is the most risky sexual practice for HIV transmission

A

receptive anal intercourse

41
Q

common sx of acute HIV infection

A
  • fever
  • lymphadenopaty
  • pharyngitis
  • rash
  • myalgia/ arthralgia
  • HA
  • less commonly oral or genital ulcers, N/V/D
42
Q

how do you screen for HIV?

A
  • 4th gen Ag/Ab testing
  • pushes back theoretical time to pos to days 16 or 17
  • MUST f/u with VL testing
  • VL ALWAYS high during acute infections
43
Q

differential dx for primary HIV infection

A
  • EBV (mono)
  • CMV
  • toxoplasmosis
  • rubella
  • syphilis
  • hepatitis
  • other viral infections
44
Q

common conditions in early symptomatic HIV

A
  • persistant vaginal candidiasis
  • oral hairy leukoplakia
  • shingles on more than one dermatome
  • cervical dysplasia or carcinoma
45
Q

AIDS defining conditions

A
  • candidiasis of bronich, trachea, lungs, esophagus
  • invasive cervical cancer
  • coccidiomycosis
  • cryptosporidiosis
  • CMV retinitis
  • encephalopathy
  • chronic herpes ulcers > 1 mo
  • histoplasmosis
  • kaposi sarcoma
  • lymphoma
  • mycobacterium
  • pneumocystis jirovecii
  • toxoplasmosis
46
Q

HIV medication categories

A
  • nRTIs (nucleoside reverse transcriptase inhibitors)
  • nnRIT
  • PI (protease inhibitor)
  • entry inhibitors
  • INSTIs (integrase strand transfer inhibitors)
47
Q

HIV treatment considerations

A
  • must be ready to start
  • tx everyone who is infected
  • consider dosing sched/ how many pills/ food
  • must include 3 active drugs to start
  • genotyping before start
48
Q

nRTIs

A
  • backbone of tx
  • all regimens have at least 2 of theses
  • all can cause metabolic acidosis- monitor bmp if someone is very sick after initiation
  • tenofovir
  • lamivudine
  • emtricitabine
  • abacavir
  • zidovudine
49
Q

tenofovir

A
  • new form= TALA
  • less toxicities
  • commonly used
  • nRTI
50
Q

lamivudine

A
  • low threshold to resistance

- nRTI

51
Q

emtricitabine

A
  • low threshold to resistance

- nRTI

52
Q

abacavir

A
  • HLA 5701 testing
  • if pos for HLA can cause cardiotoxicity
  • nRTI
53
Q

zidovudine

A
  • rarely used d/t metabolic ADRs
  • used during delivery
  • nRTI
54
Q

efavirenz

A
  • very effective
  • rash- will go away
  • vivid dreams
  • nnRTI
55
Q

etravirine

A
  • “salvage treatment”
  • effective vs. efavirenz resistant strains
  • nnRTI
56
Q

rilpivirine

A

new nnRTI

57
Q

doravarine

A

newest nnRTI

58
Q

protease inhibitors

A
  • not used bc very metabolically toxic

- usually need metabolic booster- ritonavir or cobicistat (DDI risk)

59
Q

atazanavir

A
  • can cause jaundice

- PI

60
Q

darunavir

A
  • resistant to many mutations

- PI

61
Q

INSTIs

A
  • very save, effective and well tolerated
62
Q

raltegravir

A
  • INSTI
63
Q

elvitegravir

A
  • only coformulated with cobicistat

- INSTI

64
Q

dolutegravir

A
  • most effective
  • high resistance barrier
  • BBW for use in pregnancy - neural tube defects
  • INSTI
65
Q

pictegravir

A
  • coformulated with metabolic booster

- INSTI

66
Q

entry inhibitors

A
  • maraviroc
  • blocks CCR5a receptor
  • test for tropism
67
Q

recommended starting HIV regimens

A
  • 2 nRTIs and INSTI
  • twho have boosted INSTI
  • preferred nRTI is TALA
68
Q

alternative starting HIV regimens

A
  • two NRTIs and one nnRTI
  • boosted PI plus two NRTI
  • two drug regimen if cannot use other drugs
69
Q

what should happen to the VL after initiation of HIV tx?

A
  • decrease 10 fold in first 2-4 weeks
70
Q

what do you do if a pt is failing HIV regimen?

A
  • check adherence- usually the cause

- persistent failure then should check genotype and phenotype while still on regimen